Whanin Pharm (016580) — Capital Reinvestment Ratio
Latest as of December 2025:
0.18x
Whanin Pharm (016580) has a Capital Reinvestment Ratio of 0.18x as of December 2025, meaning it reinvests 0% of its operating cash flow (₩2.38 Billion) in capital expenditures (₩419.66 Million). See free cash flow generation of Whanin Pharm to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.18x
Capex / Operating Cash Flow
Operating Cash Flow
₩2.38 Billion
KRW
Capital Expenditures
₩419.66 Million
KRW
Data as of
Dec 2025
Most recent filing
Whanin Pharm Capital Reinvestment Ratio (2009–2025)
This chart tracks Whanin Pharm's Capital Reinvestment Ratio across 14 annual periods.
Annual Capital Reinvestment Ratio for Whanin Pharm (2009–2025)
Year-by-year Capital Reinvestment Ratio for Whanin Pharm from 2009 to 2025. For live market cap and broader valuation context, see 016580 company net worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.68x | ₩9.04 Billion | ₩6.18 Billion | ▼ -51.9% |
| 2024 | 1.42x | ₩20.69 Billion | ₩29.38 Billion | ▲ +4.6% |
| 2023 | 1.36x | ₩23.20 Billion | ₩31.49 Billion | ▼ -32.0% |
| 2022 | 2.00x | ₩16.85 Billion | ₩33.65 Billion | ▲ +1507.6% |
| 2021 | 0.12x | ₩35.32 Billion | ₩4.39 Billion | ▼ -64.6% |
| 2020 | 0.35x | ₩22.75 Billion | ₩7.99 Billion | ▲ +214.5% |
| 2019 | 0.11x | ₩24.73 Billion | ₩2.76 Billion | ▼ -52.5% |
| 2018 | 0.23x | ₩17.45 Billion | ₩4.10 Billion | ▼ -71.4% |
| 2017 | 0.82x | ₩23.48 Billion | ₩19.31 Billion | ▲ +118.5% |
| 2016 | 0.38x | ₩19.82 Billion | ₩7.46 Billion | ▲ +57.1% |
| 2012 | 0.24x | ₩21.11 Billion | ₩5.06 Billion | ▲ +35.2% |
| 2011 | 0.18x | ₩15.12 Billion | ₩2.68 Billion | ▲ +0.0% |
| 2010 | 0.18x | ₩15.12 Billion | ₩2.68 Billion | ▲ +51.0% |
| 2009 | 0.12x | ₩18.61 Billion | ₩2.18 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow